Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population

Click to increase image sizeClick to decrease image size

Acknowledgment

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure statement

Dr. Alexandre Chan has consulting relationships with Eli Lilly and Company and Blueprint Medicines. Dr. Susan O’Brien has consulting relationships with Amgen, Celgene, GlaxoSmithKline, AstraZeneca, Autolus, GlaxoSmithKline, Nova Research Company, Bristol Myers Squibb, DynaMed, Eli Lilly and Company, Janssen Oncology, Johnson and Johnson, Juno Therapeutics, MEI Pharma, Inc., Merck, Aptose Biosciences, Vaniam Group, AbbVie/Genentech, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Astellas Pharma, Gilead Sciences, Pharmacyclics, TG Therapeutics, Vida Ventures, and Pfizer and has received honoraria/research funding from Alliance, Janssen, Eisai, Amgen, Loxo Oncology, Inc., Mustang Bio, Inc., Nurix Therapeutics, Inc., Astellas Pharma, Aptose Biosciences, Beigene, Ltd., Caribou Biosciences, Inc., Acerta Pharma, Regeneron, Gilead Sciences, Pfizer, AbbVie, Alexion Pharmaceuticals, TG Therapeutics, Pharmacyclics, and Kite, a Gilead company. No potential conflict of interest was reported by the author(s).

Additional information

Funding

Dr. Deepa Jeyakumar has received research funding through Pfizer and Jazz Pharmaceuticals.